Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study

Main Article Content

Kyriakos P Papadopoulos
Taofeek K Owonikoko
Melissa L Johnson
Irene Brana
Marta Gil-Martin
Raymond P Perez
Victor Moreno
April K Salama
Emiliano Calvo
Nelson S Yee
Howard Safran
Antonio Gonzalez-Martin
Raid Aljumaily
Daruka Mahadevan
Kosalai K Mohan
Jingjin Li
Elizabeth Stankevich
Israel Lowy
Matthew G Fury
Jade Homsi


cutaneous squamous cell carcinoma, non-melanoma skin cancer, safety, efficacy, PD-1


Abstract not available.


Disclosures: Study sponsored by Regeneron Pharmaceuticals Inc. and Sanofi.


Copyright 2018 SKIN

Most read articles by the same author(s)

1 2 > >>